eligibility_summary
Eligibility: CD19+ B‑cell NHL lacking options (R/R after chemo/HSCT/cell therapy, residual/relapse not HSCT‑eligible, high risk), choosing BTKi+anti‑CD19 CAR‑T, measurable disease, adequate organs, good peripheral IV, ECOG ≤2, survival ≥3 mo, age 12–75, consented. Exclude: pregnancy/plan/no contraception, active infection (HBV/HCV/HIV), autoimmune/immunodeficiency, allergy to biologics, recent trial ≤6 wks or systemic steroids ≤4 wks, serious psych/substance issues, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Ibrutinib (BTK inhibitor, oral small-molecule covalent TKI) plus anti-CD19 CAR-T cells after lymphodepleting fludarabine/cyclophosphamide. Mechanisms: Ibrutinib blocks B-cell receptor (BCR) signaling via BTK, suppressing downstream NF-kB and PI3K/AKT/mTOR pathways, reducing malignant B-cell survival, proliferation, adhesion, and chemokine-driven migration. Anti-CD19 CAR-T (autologous gene-modified T cells) redirect T-cell cytotoxicity to CD19-expressing B-NHL cells for targeted lysis. Cells/pathways targeted: CD19 on B cells, BTK within the BCR pathway, downstream NF-kB and PI3K/AKT/mTOR. Aim: synergistic killing in relapsed/refractory B-cell non-Hodgkin lymphoma.